Repare Therapeutics INC

Repare Therapeutics Inc. announced the completion of its acquisition by XenoTherapeutics, Inc., with shareholders receiving cash and contingent value rights.

Repare Therapeutics shareholders overwhelmingly approved the acquisition of the company by XenoTherapeutics, Inc. via a plan of arrangement.

Repare Therapeutics Inc. announced the sale of its RP-3467 program assets to Gilead Sciences, Inc. for up to $30 million, increasing the estimated cash payout for its pending acquisition by XenoTherapeutics.

Repare Therapeutics' Chief Scientific Officer, Dr. Michael Zinda, has resigned effective December 31, 2025, as the company prepares for its acquisition by XenoTherapeutics.

Repare Therapeutics Inc. will be acquired by XenoTherapeutics, Inc. for an estimated $1.82 per share in cash plus contingent value rights, marking the culmination of its strategic wind-up.

Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc., offering shareholders an estimated US$1.82 per share plus contingent value rights.

Repare Therapeutics announced a definitive agreement to be acquired by XenoTherapeutics, with shareholders receiving cash and contingent value rights.

Repare Therapeutics announced a net loss of $16.7 million for Q2 2025, compared to a net loss of $34.8 million in Q2 2024.

Repare Therapeutics reports Q1 2025 results, highlighted by a strategic shift towards clinical programs and cost-saving measures, including workforce reductions and out-licensing of discovery platforms.

Repare Therapeutics announced its Q3 2024 results, highlighting a strategic shift towards clinical-stage programs and providing updates on its key drug candidates.

Repare Therapeutics reported its second quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.

Repare Therapeutics reported a net income of $13.2 million for the first quarter of 2024, primarily driven by collaboration revenue, particularly from the Roche agreement.

Repare Therapeutics Inc. reports its 2024 financial results and outlines a strategic shift to focus on RP-3467 and RP-1664, involving workforce reduction and seeking partnerships for other assets.

Repare Therapeutics Inc.'s 10-K filing details the termination of the Roche collaboration for camonsertib, the advancement of lunresertib and other pipeline programs, and the company's financial position.

BVF Partners and affiliated entities have disposed of all their common shares in Repare Therapeutics Inc. following its acquisition by XenoTherapeutics, Inc. for cash and contingent value rights.

A director of Repare Therapeutics Inc. reported the disposition of common shares and stock options as part of an Arrangement Agreement for the company's acquisition.

Repare Therapeutics director Ann D. Rhoads reported the disposition of 4,000 common shares as part of an acquisition by XenoTherapeutics, Inc. for $2.20 cash and one CVR per share.

Repare Therapeutics Director Thomas Civik sold 7,500 shares as part of the company's acquisition by Xeno Acquisition Corp. for $2.20 cash and a CVR.

Repare Therapeutics' EVP and CFO, Steve Forte, disposed of all his common shares and cancelled all stock options as part of the company's acquisition by Xeno Acquisition Corp. for $2.20 cash and one CVR per share.

Repare Therapeutics SVP of Finance and CAO, Sandra Isabelle Barros Alves, reported the disposition of common shares and options following the company's acquisition by Xeno Acquisition Corp.

Repare Therapeutics has entered into an asset purchase agreement with Gilead Sciences for its RP-3467 program, generating up to $30 million and increasing the estimated cash payout to shareholders in its pending acquisition by Xeno.

Repare Therapeutics announced the resignation of its Chief Scientific Officer, Michael Zinda, effective December 31, 2025, coinciding with an update on its proposed acquisition by XenoTherapeutics.

Repare Therapeutics Inc. shareholders will vote on a proposed acquisition by Xeno Acquisition Corp. for cash and contingent value rights, or a voluntary liquidation.

Repare Therapeutics Inc. announced a definitive agreement to be acquired by XenoTherapeutics, Inc., with shareholders receiving cash and contingent value rights.

Repare Therapeutics announced significant shareholder support, totaling approximately 40% of outstanding shares, for its proposed acquisition by XenoTherapeutics, Inc.

Repare Therapeutics Inc. has entered into an Arrangement Agreement to be acquired by Xeno Acquisition Corp. for an estimated $1.82 per share cash plus contingent value rights.

BVF Partners and affiliated entities report ceasing beneficial ownership of Repare Therapeutics Inc. shares following its acquisition by XenoTherapeutics.

Biotechnology Value Fund and affiliates, holding 24% of Repare Therapeutics, sign voting agreements to support Xeno Acquisition Corp.'s takeover bid.

Versant Venture Capital and its affiliated funds have substantially decreased their beneficial ownership in Repare Therapeutics Inc. through a series of share sales in November 2025.

A group of investment entities and individuals led by MPM BioImpact LLC have significantly reduced their beneficial ownership in Repare Therapeutics Inc. through open market sales, falling below the 5% reporting threshold.

An investment group led by MPM BioImpact LLC and its affiliates, including managing directors Ansbert Gadicke, Luke Evnin, and Todd Foley, has significantly reduced its beneficial ownership in Repare Therapeutics Inc. through a series of open market share sales in January 2025.

A group of investment entities and individuals affiliated with MPM BioImpact LLC has significantly reduced their beneficial ownership in Repare Therapeutics Inc. through recent open market share sales.

Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, reporting zero beneficial ownership of Repare Therapeutics Inc. common shares as of March 31, 2026.

Shay Capital LLC and Shay Capital Holdings LLC have reported a passive beneficial ownership of 6.7% in Repare Therapeutics Inc., totaling 2,870,141 common shares.

ARK Investment Management LLC has disclosed a 4.70% passive ownership stake in Repare Therapeutics Inc. as of December 31, 2024, according to a recent Schedule 13G filing.